Short Interest in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Declines By 87.3%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 76,263 shares, a drop of 87.3% from the June 30th total of 602,285 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily trading volume, of 1,095,213 shares, the days-to-cover ratio is currently 0.1 days.

Creative Medical Technology Stock Down 0.1%

Creative Medical Technology stock traded down $0.00 during mid-day trading on Friday, reaching $0.81. The company had a trading volume of 97,253 shares, compared to its average volume of 10,137,199. Creative Medical Technology has a 52 week low of $0.78 and a 52 week high of $6.25. The company has a 50 day moving average of $1.69 and a 200-day moving average of $1.92. The firm has a market cap of $3.84 million, a price-to-earnings ratio of -0.38 and a beta of 1.89.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. On average, analysts predict that Creative Medical Technology will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.